Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.

Abstract:

:In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regulatory agency capabilities together with duplication in non-value added national regulatory requirements, particularly in low- and middle-income countries (LMICs), can slow down regulatory approvals and therefore impede patient access to new medicines. These gaps exist despite the achievements in both regulatory convergence and harmonization of technical requirements by bodies such as the International Conference on Harmonization (ICH). There is a pressing need to strengthen regulatory review systems in emerging market economies as highlighted by the World Health Organization (WHO). These diverse challenges may seem overwhelming to individual national regulators, in part because of the sheer number of initiatives by multiple stakeholders, combined with a lack of information on concise practical actionable measures that can have a positive impact on review efficiency. This commentary presents 10 pillars that we believe represent the key hallmarks of strong regulatory review systems. Leveraging our internal company expertise at the global, regional, and country level across our entire product portfolio (both innovative and generic), we selected features proven to work in leading regulatory agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which are also relevant for other regulatory authorities, especially in LMICs.

journal_name

Ther Innov Regul Sci

authors

O'Brien J,Lumsden RS,Diehl DH,Macdonald JC

doi

10.1007/s43441-019-00055-9

subject

Has Abstract

pub_date

2020-03-01 00:00:00

pages

283-292

issue

2

eissn

2168-4790

issn

2168-4804

pii

10.1007/s43441-019-00055-9

journal_volume

54

pub_type

杂志文章
  • ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.

    abstract::Attention deficit hyperactivity disorder (ADHD) is the most common neurobiological disorder in children, with a prevalence of ~6-7%1,2 that has remained stable for decades2. The social and economic burden associated with patients3, families, and broader systems (healthcare/educational) is substantial, with the annual ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015599811

    authors: Connolly JJ,Glessner JT,Elia J,Hakonarson H

    更新日期:2015-09-01 00:00:00

  • Improving Drug Development and Patient Access With the Right People, Processes, and Culture: What Needs to Happen Right Now to Bring Better Medicines to the Patients Who Need Them.

    abstract::In a global environment where health care costs are soaring, R&D efforts are flatlining. Meanwhile, payers are demanding more value for their money. In this environment, the traditional siloed drug development model is not sustainable. Yet innovations such as adaptive trial designs, real-world data collection, precisi...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018814224

    authors: Grignolo A,Siu A

    更新日期:2019-05-01 00:00:00

  • Lessons Learned From Hundreds of Thorough QT Studies.

    abstract:BACKGROUND:The coherence between the relationship of QTc and drug plasma concentration (this relationship is measured through the slope) and ICH E14 findings based on hundreds of QT study reports was studied. RESULTS:Based on ICH E14 analysis, our findings indicate that if the slope was not positive, in most cases (86...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014563549

    authors: Zhang J,Chen H,Tsong Y,Stockbridge N

    更新日期:2015-05-01 00:00:00

  • Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.

    abstract:BACKGROUND:Several articles showed that statistical efficiency of multi-arm randomized clinical trials (RCTs) is much better than conventional two-arm RCTs. Multi-arm RCTs attract interest mainly when the experimental treatment regimen is not optimized or several pipelines under development exist. Breast cancer is a po...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00141-3

    authors: Nomura S,Miyauchi Y,Ajisawa Y,Isogaya K,Sozu T

    更新日期:2020-09-01 00:00:00

  • A Practical Estimation Method for Analyzing Adverse Drug Reactions Using Data Mining.

    abstract::This study aimed to determine the potentially severe chemical properties of drugs that can cause adverse drug reactions (ADRs) such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) by using a data mining method. The study data were extracted from the Adverse Event Repor...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/0092861512460759

    authors: Shirakuni Y,Okamoto K,Uejima E,Inui S,Takahara JI,Ohgaru T,Yamasaki H,Tian Y,Kawashita N,Inoue R,Yasunaga T,Takagi T

    更新日期:2013-03-01 00:00:00

  • Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area.

    abstract:BACKGROUND:A new incentive program, "Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc," was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015600205

    authors: Shibata S,Uemura R,Suzuki T

    更新日期:2016-01-01 00:00:00

  • Validation of QT Interval Correction Methods When a Drug Changes Heart Rate.

    abstract::The QT interval is correlated with heart rate; therefore, the QT interval is usually corrected by heart rate when drug-induced QT effect is studied. Currently, there are many correction methods that use either fixed or data-driven approaches. The effectiveness of correction methods depends on many factors and varies f...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479012467018

    authors: Dang Q,Zhang J

    更新日期:2013-03-01 00:00:00

  • Principled Structured Incorporation of Clinical Knowledge Into Strategic Development Decisions.

    abstract::Efficient use of limited pharmaceutical product development resources requires integrating multiple attributes, such as efficacy, safety, pharmacology, and so on, to decide at any stage whether the development of a product should proceed aggressively or slowly or be terminated. The decision process proceeds most effec...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014558273

    authors: Gould AL,Krishna R,Khan A,Saltzman J

    更新日期:2015-03-01 00:00:00

  • Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan.

    abstract::The U.S. and Japan have preapproval access systems for patients who have exhausted approved treatment options. We compare the systems of both countries and discuss some ethical concerns surrounding non-trial access to investigational drugs. Notable points of comparison of the two countries' systems include cost of non...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00228-x

    authors: Nakada H,Folkers KM,Takashima K

    更新日期:2020-10-23 00:00:00

  • Community Opinions on the Collection and Use of Historical Control Data in Nonclinical Toxicity Studies.

    abstract:BACKGROUND:Access and use of historical control data was identified as a top stakeholder concern across organizations according to results of a survey of needs and challenges related to nonclinical data conducted by the FDA/PhUSE Nonclinical Working Group in 2011. There is a perception there may be additional ways to c...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015600203

    authors: Mihalcik LM,Bausman M,Brown P,Everds N,Feldmann J,Henck J,Potenta D,Sims J,Zandee J

    更新日期:2016-03-01 00:00:00

  • A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?

    abstract::A universal framework for the evaluation of the benefit-risk assessment of medicines during development by pharmaceutical companies and in the regulatory review by regulatory authorities is considered of value, as it would result in the systematic structured approach to support transparency in decision making. Several...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014547421

    authors: Walker S,McAuslane N,Liberti L,Leong J,Salek S

    更新日期:2015-01-01 00:00:00

  • Building an Integrated Early Clinical Development Platform to Improve the Path to Proof of Concept.

    abstract::Probability of success in phase II dominates the drug development cost calculus, with phase I/II as the critical juncture for proof of concept. Failure to address fundamental pharmacologic questions in early development is alarmingly frequent and a strong predictor of failure. Safety, manufacture, formulation, and com...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014526600

    authors: Cohen O,Sax F

    更新日期:2014-09-01 00:00:00

  • A Conditional Adaptive Weighted Test Method for Confirmatory Trials.

    abstract::The authors consider a statistically valid method that has little concern caused by down weighting in stage 2 or slight loss in efficiency and possibly improves power performance for a trial design that allows for adaptation of statistical information. In addition to the need for a priori sound data-based planning tha...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013513891

    authors: Wang SJ,Hung HMJ

    更新日期:2014-01-01 00:00:00

  • Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

    abstract:OBJECTIVE:To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations. METHODS:Studies published in English language between 1990 and 2015 were retrieved from Medline d...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1177/2168479017731583

    authors: Mehta M,Nerurkar R

    更新日期:2018-05-01 00:00:00

  • Responsibilities of Data Monitoring Committees: Consensus Recommendations.

    abstract:BACKGROUND:A data monitoring committee (DMC) has special responsibilities for protecting the safety of clinical trial participants. Few guidance documents are available that address the operations and mechanics of establishing, serving on, or reporting to a DMC. This article provides a practical guide to sponsors, inst...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479016646812

    authors: Bierer BE,Li R,Seltzer J,Sleeper LA,Frank E,Knirsch C,Aldinger CE,Levine RJ,Massaro J,Shah A,Barnes M,Snapinn S,Wittes J

    更新日期:2016-09-01 00:00:00

  • Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.

    abstract:BACKGROUND:The human papillomavirus (HPV) vaccine coverage is very low in Japan since the government suspended the active encouragement of the vaccination. We aimed to conduct a benefit-risk assessment of HPV vaccination and explore different consequent scenarios to identify potential improvements to the current Japane...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00189-1

    authors: Matsumoto T,Matsumaru N,Scuffham P,Neels P,Tsukamoto K

    更新日期:2021-01-01 00:00:00

  • A Framework for Managing the Minimal Clinically Important Difference in Clinical Trials.

    abstract::There is a long history of discussions about what is a minimal clinically important difference (MCID) and how this term applies to clinical research. This paper deals with a practical framework for MCID and its applicability to clinical trials. A literature review on the topic confirmed the fundamental role of MCID fo...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013487541

    authors: Koynova D,Lühmann R,Fischer R

    更新日期:2013-07-01 00:00:00

  • Monitoring and Evaluating the Effect of Regulatory Action: Some Recent Case Studies.

    abstract::Large electronic health care databases can be used to evaluate the effectiveness of regulatory action. Designing and interpreting such studies can be challenging. We demonstrate using case studies on modafinil, benzodiazepines, dosulepin, and piroxicam that measuring the impact of regulatory action is possible and can...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015570333

    authors: Thomson A,Meeraus WH,Wong J,Suvarna R

    更新日期:2015-07-01 00:00:00

  • An Assessment of Concerns Regarding New Regulatory Guidance for Combination Products: A Review of the Submissions Made to the FDA Regarding Their Proposed Draft New Guidance on Human Factors Studies for a Combination Product in an Abbreviated New Drug App

    abstract:BACKGROUND:The US Food and Drug Administration (FDA) put out a call for comments on new draft guidance for industry "Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA." This call for comments elicited 7 submissions from various organization...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1177/2168479018775659

    authors: Lance PT,Greenaway RV,Edwards B

    更新日期:2019-03-01 00:00:00

  • Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation.

    abstract:BACKGROUND:Communicating the clinical impact of immunogenicity in labeling is important for safe and effective use of certain prescription products. Current U.S. Food and Drug Administration (FDA) guidance does not provide comprehensive recommendations on the communication of clinical impact of immunogenicity in labeli...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00161-z

    authors: Guinn D,Madabushi R,Wang YM,Brodsky E,Zineh I,Maxfield K

    更新日期:2020-11-01 00:00:00

  • The Competence and Willingness to Consent to Research Among Patients with Heroin Dependence.

    abstract:BACKGROUND:Substance abuse research can raise ethical concerns about the comprehension and decision-making capacities of participants with drug dependence. In this study, the competence and willingness to consent to research participation were examined among patients with heroin dependence. METHODS:Twenty patients wit...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00127-1

    authors: Zhao L,Shi H,Ying B,Li Q

    更新日期:2020-09-01 00:00:00

  • Choosing a Mobile Sensor Technology for a Clinical Trial: Statistical Considerations, Developments and Learnings.

    abstract::The DIA Study Endpoints Community Working Group on Mobile Sensor Technology (MST) series addresses considerations that may be useful for selecting MST for use in a clinical trial. This article describes considerations regarding the selection of MST for clinical trials including expectations around technology specifica...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00188-2

    authors: Russell C,McCarthy M,Cappelleri JC,Wong S

    更新日期:2021-01-01 00:00:00

  • Risk-Based Monitoring (RBM) Implementation: Challenges and Potential Solutions.

    abstract::Risk-based monitoring (RBM) has disrupted the clinical trial industry, challenging conventional monitoring norms, business processes, and organizational structures. Endorsed by regulators and leading industry forums, and further driven by escalating drug development costs and enabling technology shifts making data ava...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018769284

    authors: Limaye N,Jaguste V

    更新日期:2019-03-01 00:00:00

  • Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.

    abstract::Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015578154

    authors: Klopfenstein M,Van Campen LE,Garnett T

    更新日期:2015-05-01 00:00:00

  • A Novel Collaborative Approach to Building Better Clinical Trials: New Insights From a Patient Engagement Workshop to Propel Patient-Centricity Forward.

    abstract:BACKGROUND:(1) A growing number of pharmaceutical and biotechnology organizations are engaging patients, their support networks, and clinical trial site staff at various touchpoints along the clinical research development spectrum to solicit feedback on how to reduce the burden of clinical trial participation and admin...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479019849875

    authors: Gregg A,Getz N,Benger J,Anderson A

    更新日期:2019-05-22 00:00:00

  • Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation.

    abstract::In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability. The development of regenerative medicines is v...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018779373

    authors: Vaggelas A,Seimetz D

    更新日期:2019-05-01 00:00:00

  • Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations.

    abstract::Social media presents new challenges to the biopharmaceutical industry for conducting pharmacovigilance activities. The authors reviewed worldwide regulatory guidance documents related to monitoring of adverse events posted on social media sites and identified gaps in current regulatory definitions for pharmacovigilan...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015587362

    authors: Naik P,Umrath T,van Stekelenborg J,Ruben R,Abdul-Karim N,Boland R,Ibara M,Ekuta J,Washburn D,Stergiopoulos S

    更新日期:2015-11-01 00:00:00

  • Rheumatoid Arthritis Disease Progression Modeling.

    abstract::Time progression models provide a significant advantage in developing clinical trials and can also be used to elicit comparisons among therapeutic agents. The authors performed a meta-analysis to construct a time progression model for rheumatoid arthritis (RA), an area of significant interest for pharmaceutical develo...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013499571

    authors: Reeve R,Pang L,Ferguson B,O'Kelly M,Berry S,Xiao W

    更新日期:2013-11-01 00:00:00

  • Mobile Nurse Services in Clinical Trials: Usage and Industry Perceptions.

    abstract:BACKGROUND:With the pharmaceutical industry's increased attention on enhancing patient experiences during their participation in clinical trials, the use of mobile nurse (MN) services to support the conduct of clinical trial assessments in the home (or in alternative locations other than in investigational sites) has b...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015625712

    authors: Stergiopoulos S,Eustace C,Stem K,Getz KA

    更新日期:2016-07-01 00:00:00

  • Future Perspectives for the Treatment of Diabetes: Importance of a Regulatory Framework.

    abstract:BACKGROUND:The number of diabetes patients is steadily increasing worldwide. Consequently, the social burden of diabetes is huge, requiring urgent countermeasures. We performed an intensive survey of antidiabetic drugs approved in Japan, the United States, and the European Union. METHODS:Information about approved ant...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018795854

    authors: Tsukamoto K,Cnop M,Mori D,Kume S,Anazawa T,Doi M,Chikazawa K,Matsumaru N

    更新日期:2019-07-01 00:00:00